For the third quarter of 2025, Ascendis Pharma reported a net loss of €61.0 million, or €1.00 per share basic and diluted compared to a net loss of €99.2 million, or €1.72 per share basic and diluted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback